The main endocrine drug treatments for prostate cancer are: luteinizing hormone-releasing hormone analogs, estrogens and anti-androgen drugs. The following is a list of these drugs. 1.Luteinizing hormone-releasing hormone analog (LHRH-a) Luteinizing hormone-releasing hormone analog is used for pharmacological debulking. Surgical debridement (removal of the testicles) can rapidly and consistently reduce the level of androgens in the body to very low levels (i.e., debridement levels). However, surgical depot can cause psychological problems, so nowadays it is mostly used as a drug. Some of the drugs that have been marketed include leuprolide, goserelin, and treprostinil. Depending on the dosage form, the patient will be asked to have an injection every 1, 2, 3 or 6 months. After the initial injection of LHRH-a, androgens will gradually rise and begin to fall after 1 week, reaching depleted levels by 3 to 4 weeks. 2.Estrogens Estrogens can effectively inhibit androgen activity, etc. The most commonly used estrogen is ethylene estradiol, which can achieve the same effect as depot, but due to the high incidence of cardiovascular adverse reactions of this drug, caution must be exercised in clinical application. 3, anti-androgen drugs There are two major categories of anti-androgen drugs: one is steroids, represented by megestrol acetate; the other is non-steroidal drugs, mainly bicalutamide and flutamide. The actual antiandrogen drugs play a direct competitor to androgens in the body, when androgens want to enter the cells of the prostate to play a role, it will take the first step to occupy the androgen “jobs”, so that androgens in the prostate useless. 4. Drugs for bone metastases such as zoledronic acid and disodium clodronate can be effective in treating bone metastases from prostate cancer. 5.Isotope therapy For example, strontium 89 can effectively treat prostate cancer bone metastasis. 6.New drugs for prostate cancer The drug treatment of prostate cancer is developing rapidly, and many new drugs have been successfully developed abroad and have achieved good efficacy, some of which have been marketed. For example, Abiraterone. Immunotherapy for prostate cancer has been approved by the FDA in the United States for the treatment of advanced prostate cancer.